Hakan Edstrom was appointed as MannKind’s CEO on Jan. 12 by the biomedical company’s board of directors. He retains his title of President.
Formerly the president and COO, Edstrom stepped up as CEO upon the retirement of the company’s founder, biomedical pioneer Alfred Mann. Originally from Sweden, Edstrom is a longtime resident of the Santa Clarita Valley.
"I am honored to succeed Al, an industry icon I have long admired,” Edstrom said. “I want to personally thank him for his tireless work in bringing his vision to the market and guidance over the years.”
Last fall, Edstrom told the Santa Clarita Valley Business journal that the company’s focus on diabetes began in the 1990’s when Al Mann was exposed to the technology in one of the earlier companies he had founded. In 2001 MannKind focused on the development of diabetes treatment Afrezza using an inhaler.
However, it was a long road to FDA approval and a costly development process because the biomedical firm’s Afrezza is a combination of a drug and a device proving the approval process to be more complicated. At one point it had to be reviewed by several divisions and bureaus of the FDA. One meeting Edstrom attended had 22 FDA representatives at it, he said.
The persistence paid off and in late June 2014, MannKind received FDA approval, and not long after secured a multi-million dollar licensing agreement with Paris-based Sanofi.
Under the license agreement, Sanofi gave MannKind an upfront payment of $150 million and there are potential milestone payments of up to $775 million. On Jan. 8, MannKind earned another $50 million by satisfying a manufacturing agreement under terms of the license. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65 percent and MannKind receiving 35 percent.
"I am extremely proud of all that has come to fruition at MannKind. Together with my colleagues, we have built a truly unique biopharmaceutical company with an incredibly bright future," Mann said when Edstrom’s appointment to CEO was announced.
"I have the upmost confidence in Hakan and the entire executive team who have already made great strides in achieving key milestones in bringing Afrezza through development and into commercialization. Hakan's ability to manage and grow actively marketed products while guiding the development of potential blockbuster therapies makes him an ideal fit for MannKind's next chapter of success."

